$YTENQ
YIELD10 BIOSCIENCE, INC.

2018 Q4 Form 10-Q Financial Statement

#000112170218000039 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $140.0K $76.00K $223.0K
YoY Change 40.0% -65.92% -52.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $940.0K $1.417M $1.073M
YoY Change -33.8% 32.06% -29.87%
% of Gross Profit
Research & Development $1.090M $1.340M $1.130M
YoY Change -10.66% 18.58% -27.1%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 0.0% -73.68%
% of Gross Profit
Operating Expenses $2.030M $1.417M $1.073M
YoY Change -22.81% 32.06% -29.87%
Operating Profit -$2.676M -$1.982M
YoY Change 35.02% -23.89%
Interest Expense $160.0K -$40.00K
YoY Change -2100.0%
% of Operating Profit
Other Income/Expense, Net -$130.0K $38.00K -$43.00K
YoY Change 550.0% -188.37% 437.5%
Pretax Income -$1.860M -$2.640M -$2.025M
YoY Change -27.06% 30.37% -22.47%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.860M -$2.638M -$2.030M
YoY Change -27.06% 29.95% -150.5%
Net Earnings / Revenue -1328.57% -3471.05% -910.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$7.440M -$10.56M -$22.56M
COMMON SHARES
Basic Shares Outstanding 10.03M shares 10.01M shares 2.880M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.769M $7.800M $3.000M
YoY Change -60.18% 160.0% -69.39%
Cash & Equivalents $3.023M $3.306M $2.951M
Short-Term Investments $2.746M $4.500M
Other Short-Term Assets $400.0K $400.0K $300.0K
YoY Change 33.33% 33.33% 0.0%
Inventory
Prepaid Expenses
Receivables $94.00K $54.00K $135.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.377M $8.264M $3.484M
YoY Change -57.25% 137.2% -67.07%
LONG-TERM ASSETS
Property, Plant & Equipment $1.385M $1.435M $1.587M
YoY Change -10.01% -9.58% -11.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $106.0K $69.00K
YoY Change -8.26% 53.62% -90.38%
Total Long-Term Assets $6.583M $1.873M $2.088M
YoY Change 235.01% -10.3% -29.1%
TOTAL ASSETS
Total Short-Term Assets $6.377M $8.264M $3.484M
Total Long-Term Assets $6.583M $1.873M $2.088M
Total Assets $12.96M $10.14M $5.572M
YoY Change -23.23% 81.93% -58.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $117.0K $39.00K $48.00K
YoY Change 53.95% -18.75% -79.04%
Accrued Expenses $680.0K $1.770M $1.938M
YoY Change -70.42% -8.67% -29.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.641M $1.809M $1.986M
YoY Change -30.91% -8.91% -33.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $1.000M $1.000M
YoY Change -100.0% 0.0% -49.21%
Total Long-Term Liabilities $0.00 $1.000M $1.000M
YoY Change -100.0% 0.0% -49.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.641M $1.809M $1.986M
Total Long-Term Liabilities $0.00 $1.000M $1.000M
Total Liabilities $7.262M $2.809M $3.023M
YoY Change 114.85% -7.08% -38.89%
SHAREHOLDERS EQUITY
Retained Earnings -$351.9M -$350.1M -$340.2M
YoY Change 2.68% 2.9% 2.65%
Common Stock $357.7M $357.5M $342.8M
YoY Change 0.63% 4.28% 0.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.698M $7.315M $2.549M
YoY Change
Total Liabilities & Shareholders Equity $12.96M $10.14M $5.572M
YoY Change -23.23% 81.93% -58.8%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$1.860M -$2.638M -$2.030M
YoY Change -27.06% 29.95% -150.5%
Depreciation, Depletion And Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 0.0% -73.68%
Cash From Operating Activities -$2.020M -$1.840M -$2.020M
YoY Change 6.88% -8.91% -56.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$10.00K
YoY Change 0.0% -96.97%
Acquisitions
YoY Change
Other Investing Activities $1.740M $2.000M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.740M $1.990M -$10.00K
YoY Change -20000.0% -100.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.966M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 1.960M
YoY Change -100.0% -100.0% 625.93%
NET CHANGE
Cash From Operating Activities -2.020M -1.840M -2.020M
Cash From Investing Activities 1.740M 1.990M -10.00K
Cash From Financing Activities 0.000 0.000 1.960M
Net Change In Cash -280.0K 150.0K -70.00K
YoY Change -102.45% -314.29% -101.15%
FREE CASH FLOW
Cash From Operating Activities -$2.020M -$1.840M -$2.020M
Capital Expenditures $0.00 -$10.00K -$10.00K
Free Cash Flow -$2.020M -$1.830M -$2.010M
YoY Change 6.88% -8.96% -53.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10025811 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
dei Entity Small Business
EntitySmallBusiness
true
CY2017Q3 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
5.04
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
39000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54000 USD
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1770000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
335000 USD
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
248000 USD
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
585000 USD
CY2018Q3 us-gaap Accrued Rent Current
AccruedRentCurrent
740000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 USD
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-105000 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
1 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14487000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3306000 USD
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
7797000 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9089159 shares
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355431000 USD
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
357396000 USD
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1561285 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1208817 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9102038 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8606038 shares
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29622 sqft
CY2017Q4 us-gaap Assets
Assets
16882000 USD
CY2018Q3 us-gaap Assets
Assets
10137000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14917000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
8264000 USD
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
4491 USD
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
4492 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7741000 USD
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3383000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14804000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3638000 USD
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7433084 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12180541 shares
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9143379 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10011395 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9089159 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10011395 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
91000 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2022000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6841000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2636000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7330000 USD
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
2205000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7594000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
2737000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7809000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
146000 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
3000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-19000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
646000 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
492000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-12000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-6000 USD
CY2018Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-249000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-37000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
69000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-29000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-828000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-563000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-715000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
70000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-19000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-36000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
3380000 USD
CY2018Q3 us-gaap Liabilities
Liabilities
2809000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16882000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10137000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2375000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1809000 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2018Q3 us-gaap Long Term Investments
LongTermInvestments
0 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4358000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-11166000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1954000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
118000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4534000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6309000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6731000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2025000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6844000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2630000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4215000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6754000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2661000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7388000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
252000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000 USD
CY2017Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
45000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
95000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7310000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1982000 USD
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
486000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
998000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
244000 USD
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
290000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000 USD
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
106000 USD
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000 USD
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000 USD
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000 USD
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 USD
CY2018Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
12000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
45000 USD
CY2017Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5000 USD
CY2018Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
43000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
123000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78000 USD
CY2017Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
317000 USD
CY2017Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1392000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9742000 USD
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1427000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1826 shares
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1073000 USD
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1826 shares
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
818000 USD
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
384000 USD
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1966000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13097000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1966000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
5250000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
124000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1539000 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1435000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
317000 USD
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
332000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342753000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350063000 USD
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
223000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
840000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
421000 USD
CY2016Q4 us-gaap Security Deposit
SecurityDeposit
307000 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1407000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4132000 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
400000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1063000 USD
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
356000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
952000 USD
CY2017Q3 us-gaap Share Price
SharePrice
4.00
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
4491000 USD
CY2017Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
570784 shares
CY2018Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
27500 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
28700000 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
2900000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
13502000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
7328000 USD
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2017Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
65000 USD
CY2018Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
29000 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3410847 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3035352 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10010762 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9901459 shares
CY2017Q4 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
489000 USD
CY2018Q3 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
0 USD
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
68000 USD
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
91000 USD
CY2017Q3 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1132000 USD
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
3379000 USD
CY2018Q3 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1330000 USD
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
3677000 USD
yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-584000 USD
yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-5000 USD
CY2017Q4 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1005000 USD
CY2018Q3 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1000000 USD
CY2017 yten Operating Leases Landlord Reimbursement For Lease Improvements
OperatingLeasesLandlordReimbursementForLeaseImprovements
889000 USD
CY2017 yten Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
444000 USD
yten Reversal Of Deferred Financing Costs Related To Purchase Agreement
ReversalOfDeferredFinancingCostsRelatedToPurchaseAgreement
450000 USD
yten Reversal Of Deferred Financing Costs Related To Purchase Agreement
ReversalOfDeferredFinancingCostsRelatedToPurchaseAgreement
0 USD
CY2018Q2 yten Sharebased Compensation Arrangementby Sharebased Payment Award Increase Of Shares Authorized Percent Of Outstanding Shares Percent
SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent
0.05
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company&#8217;s investment policy which establishes a concentration limit per issuer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001121702-18-000039-index-headers.html Edgar Link pending
0001121702-18-000039-index.html Edgar Link pending
0001121702-18-000039.txt Edgar Link pending
0001121702-18-000039-xbrl.zip Edgar Link pending
ex-311x20180930.htm Edgar Link pending
ex-312x20180930.htm Edgar Link pending
ex-321x20180930.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20180930.xml Edgar Link completed
yten-20180930.xsd Edgar Link pending
yten-20180930x10q.htm Edgar Link pending
yten-20180930_cal.xml Edgar Link unprocessable
yten-20180930_def.xml Edgar Link unprocessable
yten-20180930_lab.xml Edgar Link unprocessable
yten-20180930_pre.xml Edgar Link unprocessable